Gabriele M. Cerrone - SEC Form 4 Insider Trading Activity
Director, 10% Owner
IndividualBuying only
Filings (90d)
7
2 companies
Purchases
11
$176K
Sales
0
Filings (all time)
11
since 2025
Daily insider-buy trading plan - free during early access. No credit card required.
Director, 10% Owner
Updated Aug 16, 2026
Gabriele M. Cerrone has filed 7 SEC Form 4 filings across 2 companies in the last 90 days - buying. Lifetime open-market purchases: $176K. Historical track record: 3/5 stars across 9 tracked purchases.
Gabriele M. Cerrone serves as Director of Tiziana Life Sciences Ltd (TLSA). Cerrone has also held reporting roles at OKYO Pharma Ltd (OKYO) and Accustem Sciences Inc. (ACUT). Cerrone has reported 9 insider filings with the SEC since 2025. The most recent filing was in July 2026.
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realized performance after each tracked open-market purchase.
| Metric | Value |
|---|---|
| InsiderAlpha rating | ★★★☆☆ (3/5) |
| Total purchases tracked | 9 |
| Purchases with forward-return data | 9 |
| 30-day win rate | 44% |
| 90-day win rate | 100% |
| Avg 5-day return | -0.53% |
| Avg 30-day return | +10.65% |
| Avg 90-day return | +85.19% |
| Best 30-day return | +65.00% |
InsiderAlpha's records for Gabriele M. Cerrone go back to 2025: 11 primary Form 4 filings, an average of 5.5 per year. The typical open-market purchase is $16K (11 buys totaling $176K). The largest single buy on record is $45K of ACUT in 2025. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Every role Gabriele M. Cerrone has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| OKYO | OKYO Pharma Ltd | P - Open-market purchase | 25.0K | $1.40 | $35K | |
| TLSA | Tiziana Life Sciences Ltd | P - Open-market purchase | 15.0K | $1.11 | $17K | |
| TLSA | Tiziana Life Sciences Ltd | A - Grant or award | 42.4K | $0.99 | $42K | |
| OKYO | OKYO Pharma Ltd | A - Grant or award | 22.5K | $1.45 | $33K | |
| OKYO | OKYO Pharma Ltd | A - Grant or award | 25.0K | $1.40 | $35K | |
| TLSA | Tiziana Life Sciences Ltd | A - Grant or award | 15.0K | $1.11 | $17K | |
| OKYO | OKYO Pharma Ltd | A - Grant or award | 300.0K | $1.72 | $516K | |
| ACUT | Accustem Sciences Inc. | P - Open-market purchase | 9.0K | $0.83 | $7K | |
| ACUT | Accustem Sciences Inc. | P - Open-market purchase | 28.2K | $0.39 | $11K | |
| ACUT | Accustem Sciences Inc. | P - Open-market purchase | 400 | $1.10 | $440 | |
| ACUT | Accustem Sciences Inc. | P - Open-market purchase | 2.0K | $1.00 | $2K | |
| ACUT | Accustem Sciences Inc. | P - Open-market purchase | 3.0K | $0.67 | $2K | |
| ACUT | Accustem Sciences Inc. | P - Open-market purchase | 35.0K | $0.67 | $23K | |
| ACUT | Accustem Sciences Inc. | P - Open-market purchase | 35.0K | $0.65 | $23K | |
| ACUT | Accustem Sciences Inc. | P - Open-market purchase | 17.8K | $0.61 | $11K | |
| ACUT | Accustem Sciences Inc. | P - Open-market purchase | 100.0K | $0.45 | $45K |
Insiders who reported open-market trades at the companies Gabriele M. Cerrone has recently filed at. Multiple unrelated insiders buying the same stock within a short window - cluster buying - has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Gabriele M. Cerrone serves as Director of Tiziana Life Sciences Ltd (TLSA). Cerrone has also held reporting roles at OKYO Pharma Ltd (OKYO) and Accustem Sciences Inc. (ACUT). Cerrone has reported 9 insider filings with the SEC since 2025. The most recent filing was in July 2026.…
7 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 11 open-market purchases ($176K) and 0 open-market sales across all tracked filings.
Across 9 tracked purchases, Gabriele M. Cerrone averaged +10.6% avg 30-day return with a 44% 30-day win rate. InsiderAlpha rates the track record at 3/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Track every insider buy in real time, with AI-scored daily trade ideas and 10b5-1 plan flags.
Free during early access · No credit card required